U
LCTX icon

UBS’s Lineage Cell Therapeutics LCTX Stock Holding History

UBS’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$5K Buy
1,859
+248
+15% +$597 ﹤0.01% 9452
2014
Q2 		$4K Sell
1,611
-6,443
-80% -$14.6K ﹤0.01% 9671
2014
Q1 		$21K Sell
8,054
-2,973
-27% -$8.75K ﹤0.01% 8013
2013
Q4 		$32K Buy
11,027
+9,045
+456% +$27.3K ﹤0.01% 7555
2013
Q3 		$6K Sell
1,982
-8,674
-81% -$27.4K ﹤0.01% 9261
2013
Q2 		$34K Buy
+10,656
New +$34.1K ﹤0.01% 7223

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

UBS's LCTX Position: Q3 2014 in Review

UBS reduced its Lineage Cell Therapeutics (LCTX) stake by 5.8% in Q3 2014, selling an estimated $785 and leaving 5,250 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #8528.

UBS first reported a position in LCTX in Q3 2013 and has held it in 5 quarters since. The position peaked at $49K in Q1 2014. 57 funds tracked by Wall St. Rank hold LCTX as of Q3 2014.

  • UBS held 5,250 shares of Lineage Cell Therapeutics worth $13K as of Q3 2014.
  • UBS sold 326 Lineage Cell Therapeutics shares in Q3 2014, an estimated $785.
  • Lineage Cell Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8528 holding.
  • UBS first reported a position in Lineage Cell Therapeutics in Q3 2013 and has held it in 5 quarters since.
  • UBS's Lineage Cell Therapeutics position peaked at $49K in Q1 2014.
  • 57 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.